Poland · Research
Research
Molecure is a clinical-stage biotechnology company based in Warsaw, Poland. The company focuses on discovering and developing first-in-class small molecule drug candidates aimed at treating various incurable diseases, including cancer and inflammatory conditions. Molecure utilizes advanced medicinal chemistry and biology expertise to target underexplored protein targets and RNA functions. The company has a robust pipeline featuring five research programs, including two proprietary drug candidates in clinical development. OATD-01 is a dual chitinase inhibitor targeting interstitial lung diseases, currently in Phase II trials. OATD-02 is a selective dual arginase inhibitor for cancer treatment, in Phase I clinical development. Additionally, Molecure is developing an RNA-targeting platform to create small molecule compounds that interact with mRNA related to disease proteins. Molecure collaborates with leading global academic institutions and is publicly traded on the Warsaw Stock Exchange under the ticker symbol MOC. The company is committed to addressing significant unmet medical needs through innovative therapeutic solutions.
2012
Founded
Research
Industry
Poland
Location
9,601,361
Ranking
84 employees
Size
Get full access to view complete information
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams fullâmarket visibility.â
